AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD
The US Food and Drug Administration (FDA) has accepted for filing and review a new drug application for Amarin Corp Plc's Parkinson's disease treatment Zelapar.
The filing was made by Elan Pharmaceuticals Inc, which holds exclusive licence rights to market and distribute Zelapar in the US. Amarin has an exclusive option to obtain the US rights to Zelapar from Elan. Upon approval of the drug application and exercise of the option, Zelapar will be marketed by Amarin Pharmaceuticals Inc, the pharmaceutical development and marketing subsidiary of Amarin Corp Plc.
Zelapar is based …